A Phase 4 interventional study of Iloperidone in Schizophrenia and Bipolar I Disorder, sponsored by Vanda Pharmaceuticals. Recruiting at 11 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Vanda Pharmaceuticals · Phase 4, Interventional, and Treatment
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
3,471 studies on the registry are indexed under Schizophrenia; 471 are open to participants now.
This study's planned enrollment of 100 is above the median of 70 across 2,871 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Vanda Pharmaceuticals is the lead sponsor of 81 studies on the registry; 18 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 22 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Open-label iloperidone
Drug: Iloperidone
oral tablet
Also known as: VYV-683, FANAPT
Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period.
Time frame: 1 year
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanda Pharmaceuticals